CalciMedica, Inc. (CALC) News
Track canonical SquawkNews coverage tagged to CALC, CalciMedica, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CALC Calcimedica announces FDA alignment on phase 2B trial Design for auxora in acute pancreatitis and identifies disease's first potential
CALC Calcimedica announces FDA alignment on phase 2B trial Design for auxora in acute pancreatitis and identifies disease's first potential registrational endpoints Calcimedica - FDA aligns on phase 2B primary endpoint o
REGULATION | Jul 29, 2026, 11:00 AM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC
H
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers INVO Fertility (NASDAQ: IVF ) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings came out 4 days ag
EARNINGS | Jun 26, 2026, 05:05 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's intraday session, with Pulsenmore and Icecure Medical leading the gainers and Aditxt and Atlantic International among the losers
EQUITY | Jun 24, 2026, 05:05 PM UTC
M
CALC Advances Trial
CalciMedica advances trial after FDA raises no concerns over Auxora safety data
EQUITY | Jun 24, 2026, 12:36 PM UTC
M
CALC: Announces $49M Placement
CalciMedica announces private placement worth up to $49M in gross proceeds
EQUITY | Jun 24, 2026, 11:12 AM UTC
M
CALC: Continues Auxora Dosing
CalciMedica receives no FDA comments on its Phase 2 KOURAGE trial submission, allowing continued patient dosing with Auxora
EQUITY | Jun 24, 2026, 11:07 AM UTC
M
CALC: Raises $49M
CalciMedica announces private placement financing for up to approximately $49 million to advance pulmonary hypertension program
EQUITY | Jun 24, 2026, 11:03 AM UTC
M
CALC: Proceeds Auxora Dev
CalciMedica announces clinical development of Auxora may proceed following FDA review of KOURAGE trial interim safety data
EQUITY | Jun 24, 2026, 11:01 AM UTC
L
CalciMedica Issues Warrant
CalciMedica issues unregistered warrant to buy 1,000,000 shares at USD 1 each
EQUITY | Jun 24, 2026, 10:52 AM UTC